Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 9/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982105 | 0.89 | HSD17B10 (0.46) | HSD17B10HPGDMKNK2KDM4EMKNK1 | |
| SCHEMBL3980765 | 0.77 | MRGPRX1 (0.64) | HSD17B10HPGDATMMKNK2MKNK1 | |
| SCHEMBL2368112 | 0.72 | HPGD (0.57) | HSD17B10HPGDATMMKNK2KDM4E | |
| SCHEMBL4365183 | 0.70 | MRGPRX1 (0.51) | HSD17B10HPGDATMMKNK2MKNK1 | |
| SCHEMBL4902745 | 0.70 | KDR (0.57) | HSD17B10HPGDMKNK2MKNK1 | |
| SCHEMBL3979886 | 0.69 | MRGPRX1 (0.49) | HSD17B10HPGDMKNK2MKNK1ALDH1A1 | |
| SCHEMBL23630827 | 0.69 | HSD17B10 (1.00) | HSD17B10HPGDKDM4EALDH1A1MAPT | |
| SCHEMBL4081930 | 0.66 | ALDH1A1 (0.57) | HSD17B10HPGDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3977843 | 0.66 | HSD17B10 (0.48) | HSD17B10HPGDATMMKNK2KDM4E | |
| SCHEMBL8241663 | 0.66 | HSD17B10 (0.56) | HSD17B10HPGDATMMKNK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | AHR, MALT1, ABL1 | HSD17B10 1698/4885HPGD 1495/4885ATM 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.